ArticleScientific reports2025
Combined treatment using bismuth sulfide nanoparticles loaded with NANOG decoy oligodeoxynucleotides under X-ray radiation for breast cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual-targeted glutathione-glutamate functionalized Bismuth-Niosomes hybrid nanosystem for co-delivery of doxorubicin and Pi3K inhibitor into U87 glioblastoma cells.Scientific reports · 2026Article
- The NF-κB Signalling Pathway: Mechanisms, Consequences and Therapeutic Targets.Journal of cellular and molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Our goal in this study was to develop bismuth sulfide nanoparticles (NPs) that were functionalized with chitosan and incorporated with decoy oligodeoxynucleotides (ODNs) specifically targeting the NANOG transcription factor (designated as Bi@Chi-DEC NPs) in triple-negative breast cancer cells. FT-IR, UV-vis, FESEM, EDX, TEM, DLS, release kinetics, and hemolysis assays were done to validate the successful synthesis of Bi@Chi-DEC NPs. The synthesized spherical particles exhibited a size distribution averaging 213.8 nm, with a zeta potential measured at -3.27 mV. The anticancer properties of the synthesized nanoparticles, along with X-ray irradiation (2Gy), were assessed through a series of cellular assays, including MTT, cellular uptake, apoptosis, cell cycle analysis, scratch, and tumorsphere formation assays on MDA-MB-231 breast cancer cells. Treatment with the synthesized nanoparticles and X-irradiation resulted in a significant reduction in cell viability, tumorsphere formation, and cellular migration, while concurrently enhancing the rate of apoptotic cells and inducing cell cycle arrest at the G2/M phase. It can be inferred that Bi@Chi-DEC NPs possess the potential to serve as a therapeutic modality for cancer treatment, particularly when utilized along with radiation therapy. Further, in vivo studies are warranted to substantiate the efficacy of this therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.